Plixorafenib is a next-generation, selective BRAF kinase inhibitor designed to treat various cancers driven by BRAF V600 and other Class 1 or Class 2 mutations. As a novel paradox and dimer breaker, it… Read more
Plixorafenib is a next-generation, selective BRAF kinase inhibitor designed to treat various cancers driven by BRAF V600 and other Class 1 or Class 2 mutations. As a novel paradox and dimer breaker, it works by inhibiting ERK signaling in tumor cells while sparing normal cells, providing a targeted approach for patients with limited treatment options. To support the rigorous demands of pharmaceutical research and development, our collection includes essential Plixorafenib-related compounds, such as high-purity impurities, metabolites, and stable isotope-labelled standards. These materials are critical for laboratories engaged in accurate impurity profiling, analytical method validation, and routine quality control. By utilizing these characterized reference standards, researchers can effectively identify and quantify degradation products and metabolic pathways, ensuring consistent performance in high-performance liquid chromatography and other analytical assays throughout the drug development lifecycle and regulatory submission process.